Literature DB >> 28066572

Ticagrelor and heart surgery controversy: we may have better antiplatelet options.

Victor Serebruany1, Naida Bulaeva2, Elena Golukhova2.   

Abstract

Year:  2016        PMID： 28066572      PMCID： PMC5179469          DOI： 10.21037/jtd.2016.11.26

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  14 in total

1.  Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

Authors:  Pierluigi Tricoci; Zhen Huang; Claes Held; David J Moliterno; Paul W Armstrong; Frans Van de Werf; Harvey D White; Philip E Aylward; Lars Wallentin; Edmond Chen; Yuliya Lokhnygina; Jinglan Pei; Sergio Leonardi; Tyrus L Rorick; Ann M Kilian; Lisa H K Jennings; Giuseppe Ambrosio; Christoph Bode; Angel Cequier; Jan H Cornel; Rafael Diaz; Aycan Erkan; Kurt Huber; Michael P Hudson; Lixin Jiang; J Wouter Jukema; Basil S Lewis; A Michael Lincoff; Gilles Montalescot; José Carlos Nicolau; Hisao Ogawa; Matthias Pfisterer; Juan Carlos Prieto; Witold Ruzyllo; Peter R Sinnaeve; Robert F Storey; Marco Valgimigli; David J Whellan; Petr Widimsky; John Strony; Robert A Harrington; Kenneth W Mahaffey
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

Review 2.  Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting in the Setting of Acute Coronary Syndrome.

Authors:  Ritin Bomb; Carrie S Oliphant; Rami N Khouzam
Journal:  Am J Cardiol       Date:  2015-04-08       Impact factor: 2.778

3.  Vorapaxar in the secondary prevention of atherothrombotic events.

Authors:  David A Morrow; Eugene Braunwald; Marc P Bonaca; Sebastian F Ameriso; Anthony J Dalby; Mary Polly Fish; Keith A A Fox; Leslie J Lipka; Xuan Liu; José Carlos Nicolau; A J Oude Ophuis; Ernesto Paolasso; Benjamin M Scirica; Jindrich Spinar; Pierre Theroux; Stephen D Wiviott; John Strony; Sabina A Murphy
Journal:  N Engl J Med       Date:  2012-03-24       Impact factor: 91.245

Review 4.  Off-pump versus on-pump coronary artery bypass grafting.

Authors:  Christian H Møller; Daniel A Steinbrüchel
Journal:  Curr Cardiol Rep       Date:  2014-03       Impact factor: 2.931

5.  Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial?

Authors:  Victor L Serebruany
Journal:  Am Heart J       Date:  2011-01       Impact factor: 4.749

Review 6.  Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era.

Authors:  Ilke Sipahi; M Hakan Akay; Sinan Dagdelen; Arie Blitz; Cem Alhan
Journal:  JAMA Intern Med       Date:  2014-02-01       Impact factor: 21.873

7.  Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).

Authors:  Vijay Kunadian; Stefan K James; Daniel M Wojdyla; Cafer Zorkun; Jinhui Wu; Robert F Storey; Ph Gabriel Steg; Hugo Katus; Hakan Emanuelsson; Jay Horrow; Juan Maya; Lars Wallentin; Robert A Harrington; C Michael Gibson
Journal:  JACC Cardiovasc Interv       Date:  2013-07       Impact factor: 11.195

Review 8.  Ticagrelor for acute coronary syndromes.

Authors:  Sameer Bansilal; Marc P Bonaca; Marc S Sabatine
Journal:  Expert Rev Cardiovasc Ther       Date:  2013-10-23

9.  Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials.

Authors:  Subodh Verma; Michael E Farkouh; Bobby Yanagawa; David H Fitchett; Muhammad R Ahsan; Marc Ruel; Sachin Sud; Milan Gupta; Shantanu Singh; Nandini Gupta; Asim N Cheema; Lawrence A Leiter; Paul W M Fedak; Hwee Teoh; David A Latter; Valentin Fuster; Jan O Friedrich
Journal:  Lancet Diabetes Endocrinol       Date:  2013-09-13       Impact factor: 32.069

10.  A Novel Inhibitor of Protease-activated Receptor 1: A Review of Chemical Structure and Mode of Action.

Authors:  Mehrnoosh Hashemzadeh; Joseph M Arreguin; Tyler Roberts; Mohammad Reza Movahed
Journal:  Rev Cardiovasc Med       Date:  2015       Impact factor: 2.930
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.